Navigation Links
NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Date:10/25/2007

olite, effectively inhibiting the cellular replication process in solid tumors. These findings validate the potential of our small molecule PEGylation technology platform to improve a wide range of oncolytics in critical cancer treatment regimens."

NKTR-102 Preclinical Studies

Preclinical studies in mouse xenograft tumor models evaluated comparative anti-tumor activity and pharmacokinetics of NKTR-102 and irinotecan as compared to controls. In each model, a single IV administration of NKTR-102 on days 0, 4 and 8 in tumor-bearing mice resulted in substantial tumor growth inhibition in a statistically-significant dose-related manner. Anti-tumor activity was measured as changes in tumor weight, tumor growth inhibition and tumor regression.

In all models, NKTR-102 was well-tolerated with no drug toxicity deaths.

Anti-Tumor Activity of NKTR-102 in Mouse Xenograft Models of Human Colorectal, Lung and Breast Tumors

In the colorectal and lung cancer models, NKTR-102 inhibited tumor growth at all dose levels with 94% tumor suppression at the highest dose of 90 mg/kg relative to controls. Tumor regression was also observed with NKTR-102 at this same dose level, while no regression was observed with irinotecan administration. Irinotecan dosing at 90 mg/kg resulted in only modest tumor growth inhibition of 6% in colorectal and 24% in lung.

In the breast cancer model, NKTR-102 suppressed tumor growth by 92% at all dose levels relative to controls with irinotecan only resulting in tumor growth inhibition of up to 56%.

Favorable Pharmacokinetics of NKTR-102 in Lung and Colorectal Mouse Xenograft Models

Following NKTR-102 administration, exposure to the active metabolite of irinotecan in colorectal and lung tumor tissue was increased substantially relative to irinotecan. In colorectal tumor tissue, the effective half-life of the metabolite was increased from 4 hours with irinotecan to 15 days with NKTR-102. In lung tumor tissue, the e
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Sept. 4, 2015  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA) of 2015, which ... pending at the FDA to twenty-nine. ... commented, "We believe our current pipeline of twenty-nine submissions, ...
(Date:9/4/2015)... , Sep. 04, 2015 ... the addition of the "Stability Testing of Pharmaceuticals ... their offering. By attending this comprehensive two ... to design efficient stability studies that are suitable for ... appropriate stability studies and manage stability samples and facilities ...
(Date:9/3/2015)... MUMBAI, India , Sept. 3, 2015  Cipla, ... to meet the everyday needs of all patients, today ... into definitive agreements to acquire two US-based companies, InvaGen ... subject to certain closing conditions, is valued at $550 ... combined revenue from these transactions is over $200 million ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Seventh ANDA Submission Of 2015 2Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5
... announces that a new market research report is available ... Discoveries: what the future holds ... Original analysis of the clinical potential and commercial prospects ... current market context Original analysis of the ...
... 2011 Reportlinker.com announces that a new market ... Levosimendan - Comprehensive patent search ... Eliminate unnecessary risk with the industry benchmark in ... a regularly updated, professional patent search performed by ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 2Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 3Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 4Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 5Reportlinker Adds Levosimendan - Comprehensive patent search 2Reportlinker Adds Levosimendan - Comprehensive patent search 3Reportlinker Adds Levosimendan - Comprehensive patent search 4
(Date:9/4/2015)... PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for a ... could be their solution. , The patent-pending K Med Cups provide a quick and simple ... help to relieve a cold, flu or cough. As a result, they enhance comfort and ...
(Date:9/4/2015)... ... 04, 2015 , ... Having access to a doctor can sometimes be a ... of unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to ... a solution to alleviate this problem has recently presented itself, the new telemedicine platform ...
(Date:9/4/2015)... ... September 04, 2015 , ... Compliance officers deal with many ... Stark physician self-referral law. “Stark Law DOs and DON’Ts: Best Practices for ... Inc. (AIS), will detail which deals are attracting the most government scrutiny and ...
(Date:9/4/2015)... GENEVA, IL (PRWEB) , ... September 04, 2015 , ... ... in Geneva, IL hosting Generation Rescue’s A Night of Hope event supporting families affected ... Ed French and Rowena and Joe Salas, joined together at the Oscar Swan Inn ...
(Date:9/3/2015)... ... 03, 2015 , ... TransPack Toon gives users a set of 90 cartoon ... framing transitions in 30 different styles. Presets range from snow, underwater, forest, futuristic, city ... TransPack Toon features 90 cartoon transitions from 30 unique styles. Editors can choose ...
Breaking Medicine News(10 mins):Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2Health News:Pixel Film Studios Releases TransPack Toon, a New FCPX Transition 2
... Oct. 29 Nu Skin Enterprises, Inc. (NYSE: ... Angeles with record attendance, record product sales and record ... convention attracted more than 12,000 distributors from the company,s ... came from the United States, Japan and Korea. , ...
... MN,s First Lady salutes ... ... and her daughter,s vow to help children and families struggling with chronic illness has progressed into ... Pawlenty. , , , , ,Mrs. Pawlenty, a strong supporter of The Priyanka Foundation ...
... apt to give needed treatment, and faster, study finds , ... to a designated stroke center are much more likely to ... nearest hospital, says a new study. , If given within ... activator) can reduce stroke-related disability. , The study grew out ...
... 29 Five-time Olympic gold medalist speed skater and ... fitness column for Tribune Media Services (TMS), which plans ... the United States and abroad beginning Tuesday, November 3. ... week Heiden will offer readers advice on lifelong fitness ...
... Tenn., Oct. 29 Smith & Nephew,s (NYSE: ... has made a first-of-its-kind contribution to the Center for ... grants. , Smith & Nephew and COTA entered ... COTA will serve as an independent, third-party administrator of ...
... statement from 60 Plus Association President Jim Martin: , "There is an ... the truth can get its shoes on. The truth has ... I,m putting the wood to this lie right now, the Speaker,s ... , "Speaker Pelosi, I challenge you to tell the ...
Cached Medicine News:Health News:Nu Skin Celebrates Record-Breaking Global Convention 2Health News:Nu Skin Celebrates Record-Breaking Global Convention 3Health News:Nu Skin Celebrates Record-Breaking Global Convention 4Health News:Nu Skin Celebrates Record-Breaking Global Convention 5Health News:Minnesota Charity Launches Global Initiative to Help Children and Families Fighting Chronic Illnesses 2Health News:Stroke Centers May Offer Best Shot at Recovery 2Health News:Eric Heiden Column To Debut November 3 2Health News:Eric Heiden Column To Debut November 3 3Health News:Smith & Nephew Orthopaedics Donates Inaugural Funds to COTA Grants Program 2Health News:Smith & Nephew Orthopaedics Donates Inaugural Funds to COTA Grants Program 3
... Pipettor is the #1 Pipettor for ... comfort, and reliability. Continuously adjustable. Features ... sub-micrometer. Easy interchangeable ejector buttons to ... Adjustable rapid pipet tip ejector with ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,408-9) or contact custom...
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 0.5-10 microliter range....
Medicine Products: